Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q4 2023 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a report issued on Wednesday, February 1st. Jefferies Financial Group analyst M. Raycroft forecasts that the biopharmaceutical company will post earnings per share of ($1.37) for the quarter. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($8.84) per share.
Get Ultragenyx Pharmaceutical alerts:Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last released its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.29) by ($0.14). Ultragenyx Pharmaceutical had a negative return on equity of 84.14% and a negative net margin of 197.47%. The business had revenue of $90.70 million during the quarter, compared to the consensus estimate of $98.76 million.
Several other research firms also recently commented on RARE. Morgan Stanley reduced their price objective on Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an "overweight" rating for the company in a report on Friday. Wedbush reissued a "neutral" rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, October 13th. The Goldman Sachs Group dropped their target price on Ultragenyx Pharmaceutical from $74.00 to $55.00 and set a "neutral" rating on the stock in a research report on Friday, November 4th. StockNews.com raised Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research report on Monday, January 30th. Finally, Cowen dropped their target price on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a research report on Thursday, November 3rd. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $91.69.Ultragenyx Pharmaceutical Stock Performance
NASDAQ RARE opened at $45.73 on Friday. Ultragenyx Pharmaceutical has a one year low of $33.36 and a one year high of $85.53. The stock has a 50-day moving average of $43.04 and a 200 day moving average of $43.66. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -4.70 and a beta of 0.96.
Insiders Place Their Bets
In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 2,031 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Wednesday, December 21st. The stock was sold at an average price of $43.96, for a total value of $89,282.76. Following the sale, the chief accounting officer now owns 16,197 shares of the company's stock, valued at approximately $712,020.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.70% of the company's stock.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
Several large investors have recently modified their holdings of RARE. Raymond James & Associates increased its position in shares of Ultragenyx Pharmaceutical by 46.0% during the 1st quarter. Raymond James & Associates now owns 13,882 shares of the biopharmaceutical company's stock valued at $1,008,000 after purchasing an additional 4,373 shares during the last quarter. US Bancorp DE increased its position in shares of Ultragenyx Pharmaceutical by 14.6% during the 1st quarter. US Bancorp DE now owns 8,611 shares of the biopharmaceutical company's stock valued at $625,000 after purchasing an additional 1,097 shares during the last quarter. Bank of Montreal Can boosted its holdings in Ultragenyx Pharmaceutical by 22.7% during the 1st quarter. Bank of Montreal Can now owns 40,319 shares of the biopharmaceutical company's stock valued at $2,927,000 after acquiring an additional 7,469 shares during the period. MetLife Investment Management LLC purchased a new position in Ultragenyx Pharmaceutical during the 1st quarter valued at $252,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Ultragenyx Pharmaceutical by 44.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 463,996 shares of the biopharmaceutical company's stock valued at $33,693,000 after acquiring an additional 141,945 shares during the period. Institutional investors own 93.17% of the company's stock.
About Ultragenyx Pharmaceutical
(Get Rating)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Read More
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.